Navigation Links
Kensey Nash to Participate in the Sidoti Thirteenth Annual New York Emerging Growth Institutional Investor Forum Conference
Date:3/13/2009

EXTON, Pa., March 13 /PRNewswire-FirstCall/ -- Kensey Nash Corporation (Nasdaq: KNSY) is scheduled to present at the Sidoti Thirteenth Annual New York Emerging Growth Institutional Investor Forum at The Grand Hyatt in New York City on Tuesday, March 24, 2009.

Joseph W. Kaufmann, Kensey Nash's CEO, will deliver the Company's presentation, beginning at approximately 11:35 a.m. (ET). The presentation materials will be available on the company's website (www.kenseynash.com) beginning at 11:35 a.m. (ET) on Tuesday, March 24, 2009.

About Kensey Nash Corporation. Kensey Nash Corporation is a leading medical technology company providing innovative solutions and technologies for a wide range of medical procedures. The Company provides an extensive range of products into multiple medical markets, primarily sports medicine, spine, and endovascular markets. Many of the products are based on the Company's significant expertise in the design, development, manufacturing and processing of absorbable biomaterials, which has led to partnerships to commercialize technologies. The Company is known as a pioneer in the field of arterial puncture closure, as the inventor and developer of the Angio-Seal(TM) Vascular Closure Device, which is licensed to St. Jude Medical, Inc.


'/>"/>
SOURCE Kensey Nash Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Kensey Nash Announces Appointment of Chief Financial Officer
2. Kensey Nash to Present at the Canaccord Adams Musculoskeletal Conference
3. Kensey Nash Announces Director Resignation
4. Kensey Nash Corporation Announces Its Second Quarter 2009 Earnings Release Date and Teleconference
5. Kensey Nash to Participate in the RBC Capital Markets Healthcare Conference
6. Kensey Nash Corporation Announces its Fourth Quarter and Fiscal Year End 2008 Earnings Release Date and Teleconference
7. Kensey Nash Provides 4th Quarter Fiscal 2008 and Fiscal Year 2009 Guidance
8. Kensey Nash Announces the Closing on its Sale of the Endovascular Business to Spectranetics
9. Kensey Nash to Participate in the Friedman Billings Ramsey 12th Annual Spring Investor Conference
10. Corrected Press Release: Kensey Nash to Present at the Bank of America 2008 Health Care Conference
11. Kensey Nash to Present at the Bank of America 2008 Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty ... Barry M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... and the most handsome men, look naturally attractive. Plastic surgery should be invisible.” ...
(Date:6/24/2016)... Frederick, Maryland (PRWEB) , ... June 24, 2016 ... ... Mid-Atlantic Angels is actively feeding the Frederick area economy by obtaining investment capital ... support over the past 2½ years that have already resulted in more than ...
(Date:6/24/2016)... ... 2016 , ... Venture Construction Group (VCG) sponsors Luke’s Wings ... at the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The ... members that have been wounded in battle and their families. Venture Construction Group is ...
(Date:6/24/2016)... ... June 24, 2016 , ... Advanced Plastic Surgery ... Arizona pageant as its official Medspa Sponsor. Dr. Josh Olson, a board-certified plastic ... , Dr. Olson says the decision to support the pageant in an ...
(Date:6/24/2016)... ... June 24, 2016 , ... To succeed under value-based ... however, are unsure how to move forward, given the need to sustain current ... forward tailored to an organization’s specific needs. , PYA Principal Martie Ross states, ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology: